A Phase 2 interventional study of SNG001 and Placebo in Viral Pneumonia, sponsored by Synairgen Research Ltd.. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Synairgen Research Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Pneumonia, Viral with a site in United States — 5 open to participants now, 6 under way, 3 of them phase 3. Pneumonia, Viral · United States.
Among the 33 studies in Pneumonia, Viral with a site in United States, this one is the 19th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 2, and was the 31st registered.
156 studies on the registry are indexed under Pneumonia, Viral; 13 are open to participants now.
Browse Pneumonia, Viral studies →5 of the 33 studies in Pneumonia, Viral with a site in United States are open now. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
All Natural Medicine Clinic, LLC · Sites in United States
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Pneumonia, Viral studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 8 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 76 across 88 interventional studies indexed under Pneumonia, Viral.
Median enrollment 50 across the 27 interventional studies, 250 across the 5 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 33 have an industry lead sponsor. The 10 most frequent:
Synairgen Research Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Synairgen Research Ltd. has 1 study filed under Pneumonia, Viral — fewer than ten, so there is no comparison to draw.
5 of the studies in Pneumonia, Viral with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Pneumonia, Viral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied.
The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo.
In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital.
In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.
Part 1 Inclusion Criteria:
To be eligible for randomisation into Part 1 of this study, each participant must fulfil the following criteria:
Part 1 Exclusion Criteria:
A participant must not be randomised into Part 1 of the study if they meet any of the following criteria:
Immunocompromising condition, including:
Part 2 Inclusion Criteria:
To be eligible for randomisation into Part 2 of this study, each participant must fulfil the following criteria:
1.a Patients ≥18 and \<50 years of age at the time of consent, with an immunocompromising condition, including:
Corticosteroids >20 mg of prednisone or equivalent per day, administered continuously for >14 days prior to randomisation or
Part 2 Exclusion Criteria:
A participant must not be randomised into Part 2 of the study if they meet any of the following criteria:
Immunocompromising condition, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will inhale a dose of SNG001 via the nebuliser, once a day for up to 14 days. A first, single syringe, low-dose cohort may be followed by an optional second cohort utilising a two-syringe dose.
Drug: SNG001
Participants will inhale a dose of placebo matched to SNG001 (only excipients of the SNG001 solution) via the nebuliser, once a day for up to 14 days.
Drug: Placebo
Participants will inhale the higher (two-syringe) dose of SNG001 via the nebuliser, once a day for up to 14 days.
Drug: SNG001
Participants will inhale a dose of placebo matched to SNG001 (only excipients of the SNG001 solution) via the nebuliser, once a day for up to 14 days
Drug: Placebo
Drug pages: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing drug product solution of IFNβ 1a.
The placebo nebuliser solution is presented in glass syringes containing solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).
Part 1: AE and SAE Severity
The occurrence and severity of AEs and serious adverse events (SAEs), including pre-specified respiratory and cardiovascular deteriorations.
Time frame: Up to 28 days from randomisation
Part 2: All-cause Mortality
All deaths recorded on study
Time frame: Within 28 days from randomisation
Part 2: AE and SAE Severity
The occurrence and severity of AEs and SAEs, including pre-specified respiratory and cardiovascular deteriorations.
Time frame: Up to 42 days from randomisation
Part 2: Change in mSOFA From Baseline
Change from baseline in modified Sequential Organ Failure Assessment (mSOFA) score during ICU (intensive Care Unit) stay.
Time frame: Up to 14 days
Part 2: Time to Extubation
Time to extubation.
Time frame: Up to 28 days from randomisation
Part 2: Number of Ventilator Free Days
Ventilator-free days over 28 days from randomisation
Time frame: Up to 28 days from randomisation
Part 2: Duration of Stay in ICU
Duration of ICU stay measured from time of admission until discharge.
Time frame: Up to 28 days from randomisation
Part 2: Duration of Stay in Hospital
Duration of hospital stay measured from time of admission until discharge.
Time frame: Up to 28 days from randomisation
Part 2: Change in OSCI From Baseline
Change in Ordinal Scale for Clinical Improvement (OSCI) score from baseline to 7, 10, 14 and 28 days post randomisation.
Time frame: Up to 28 days from randomisation
Part 2: Time to First Negative Virus Test
Time to first negative virus test in tracheal aspirates.
Time frame: Up to 14 days from randomisation
Part 2: Change in IFNβ Levels From Baseline
Change from baseline in levels of IFNβ dependent biomarkers in tracheal aspirates
Time frame: Up to 14 days from randomisation
Part 2: No Organ Support
Alive and free of organ support
Time frame: At 28 days from randomisation and at 28 days post final dose
Part 2: All Cause Mortality
All deaths recorded post final dose
Time frame: Within 28 days post final dose
| Milestone | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) | Part 2 Efficacy Evaluation of SNG001 | Part 2 Efficacy Evaluation of SNG001 (Placebo) |
|---|---|---|---|---|
| Started | 8 | 3 | 0 | 0 |
| Completed | 8 | 3 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
The occurrence and severity of AEs and serious adverse events (SAEs), including pre-specified respiratory and cardiovascular deteriorations.
| Participants | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) |
|---|---|---|
| Any TEAE | 8 | 2 |
| Mild TEAE | 2 | 2 |
| Moderate TEAE | 2 | 2 |
| Severe TEAE | 7 | 2 |
| Any serious TEAE | 7 | 2 |
| Any fatal TEAE | 4 | 1 |
| Any related fatal TEAE | 0 | 0 |
| Any TEAE related to study treatment | 1 | 0 |
| Any TEAE leading to discontinuation of study treatment | 1 | 0 |
| Any TEAE of note | 0 | 0 |
All deaths recorded on study
No measurements were reported for this outcome.
The occurrence and severity of AEs and SAEs, including pre-specified respiratory and cardiovascular deteriorations.
No measurements were reported for this outcome.
Change from baseline in modified Sequential Organ Failure Assessment (mSOFA) score during ICU (intensive Care Unit) stay.
No measurements were reported for this outcome.
Time to extubation.
No measurements were reported for this outcome.
Ventilator-free days over 28 days from randomisation
No measurements were reported for this outcome.
Duration of ICU stay measured from time of admission until discharge.
No measurements were reported for this outcome.
Duration of hospital stay measured from time of admission until discharge.
No measurements were reported for this outcome.
Change in Ordinal Scale for Clinical Improvement (OSCI) score from baseline to 7, 10, 14 and 28 days post randomisation.
No measurements were reported for this outcome.
Time to first negative virus test in tracheal aspirates.
No measurements were reported for this outcome.
Change from baseline in levels of IFNβ dependent biomarkers in tracheal aspirates
No measurements were reported for this outcome.
Alive and free of organ support
No measurements were reported for this outcome.
All deaths recorded post final dose
No measurements were reported for this outcome.
Collected over All adverse events for Part 1 of the study were collected 28 days from randomisation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Safety Evaluation of SNG001 | 4/8 (50%) | 7/8 (87.5%) | 8/8 (100%) |
| Part 1 Safety Evaluation of SNG001 (Placebo) | 1/3 (33.3%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/8 | 1/3 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/8 | 1/3 |
| Cardiac failureCardiac disorders | 0/8 | 1/3 |
| Cardiac failure acuteCardiac disorders | 0/8 | 1/3 |
| Multiple organ dysfunction syndromeGeneral disorders | 2/8 | 0/3 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 0/3 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/8 | 0/3 |
| Hepatic steatosisGastrointestinal disorders | 1/8 | 0/3 |
| Herpes simplex meningoencephalitisNervous system disorders | 1/8 | 0/3 |
| Klebsiella urinary tract infectionInfections and infestations | 1/8 | 0/3 |
| Event | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/8 | 1/3 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/8 | 1/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/8 | 1/3 |
| Cardiac failureCardiac disorders | 0/8 | 1/3 |
| Cardiac failure acuteCardiac disorders | 0/8 | 1/3 |
| Oral herpesSkin and subcutaneous tissue disorders | 0/8 | 1/3 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/8 | 1/3 |
| Respiratory acidosisRespiratory, thoracic and mediastinal disorders | 0/8 | 1/3 |
| Superficial vein thrombosisBlood and lymphatic system disorders | 0/8 | 1/3 |
| Multiple organ dysfunction syndromeGeneral disorders | 2/8 | 0/3 |
Part 2 was not conducted. Study was terminated due to significantly low patient recruitment rate.
| Age, Continuous(Years) | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) | Part 2 Efficacy Evaluation of SNG001 | Part 2 Efficacy Evaluation of SNG001 (Placebo) | Total |
|---|---|---|---|---|---|
| Mean | 66.5 ± 13.95 | 63.67 ± 11.72 | — | — | 65.09 ± 13.13 |
| Sex: Female, Male(Participants) | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) | Part 2 Efficacy Evaluation of SNG001 | Part 2 Efficacy Evaluation of SNG001 (Placebo) | Total |
|---|---|---|---|---|---|
| Female | 4 | 2 | 0 | 0 | 6 |
| Male | 4 | 1 | 0 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) | Part 2 Efficacy Evaluation of SNG001 | Part 2 Efficacy Evaluation of SNG001 (Placebo) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 0 | 0 | 4 |
| White | 4 | 2 | 0 | 0 | 6 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Safety Evaluation of SNG001 | Part 1 Safety Evaluation of SNG001 (Placebo) | Part 2 Efficacy Evaluation of SNG001 | Part 2 Efficacy Evaluation of SNG001 (Placebo) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 8 | 2 | 0 | 0 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2025 to primary completion in Mar 2026, 6 months.
Results were first posted in Sep 2026, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001
Synairgen Research Ltd.